The FDA approved selumetinib as treatment for pediatric neurofibromatosis type 1, expanding options for young patients with inoperable plexiform neurofibromas.
Approval Alert | Selumetinib in Pediatric NF1-PNs
Advertisement
Advertisement
Trending on CancerNetwork
1
Lenvatinib/Pembrolizumab Shows Promise After IO Progression in GYN Cancers
2
Lymphoma's Revolution: Evens & Rhodes on CLL, CAR-T, and NJ Care
3
Making Nuanced Decisions on CAR-T and Bispecifics in Multiple Myeloma
4
How Have Bispecific Antibodies Evolved in Multiple Myeloma?
5